Skip to content

Effect of intensive versus standard blood pressure intervention on cardiovascular disease regression in the very elderly hypertensive patients

A randomized controlled study on the efficacy and safety of enhanced blood pressure comparison standard in hypertensive patients aged 80 years and over

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062039
Enrollment
Unknown
Registered
2022-07-20
Start date
2022-07-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Standard treatment:Systolic blood pressure < 150mmHg
Standard treatment:Systolic blood pressure < 130mmHg

Sponsors

Daping Hospital Affiliated to Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
80 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Men or women aged =80 years at the time of randomization. There is no upper age limit. To ensure that the patients are aged =80 years their date of birth will need to be confirmed by an official national document. 2. Hypertensive patients with SBP from 140 to 199 mmHg without medication or patients undergoing antihypertensive treatment. 3. Signed the written informed consent.

Exclusion criteria

Exclusion criteria: 1.SBP = 200 mmHg, or DBP 2.5mg/dl[> 221 µ mol/L]); 8. Symptomatic heart failure or reduced left ventricular ejection fraction (<40%) within the past 6 months; 9. Diagnosed atrial fibrillation; 10. Previous antihypertensive treatment with hypotensive events at SBP = 130 mmHg or clear evidence of intolerance of SBP = 130 mmHg; 11. Patients with a history of allergy to the study drug; 12. Participating in other clinical trials; 13. Unable to live in the selected center for a long time during the study period, which is not conducive to follow-up; 14. Patients with disabilities, mobility impairments, mental retardation, and other factors that may prevent them from participating in the study; 15. Patients with a poor compliance or otherwise deemed unsuitable for clinical trials by the investigator.

Design outcomes

Primary

MeasureTime frame
Blood pressure;Nonfatal stroke;Non fatal myocardial infarction;Acute heart failure;Coronary revascularization;Cardiovascular death;

Secondary

MeasureTime frame
Unstable angina pectoris;transient ischemic attack(TIA);New lacunar cerebral infarction;Hospitalization due to end point event;New onset atrial fibrillation;New onset diabetes;Decline of renal function or development of end-stage renal disease;All cause mortality;Routine blood test;electrolyte;Blood glucose;Blood lipid;Renal function;Hepatic function;

Countries

China

Contacts

Public ContactZeng Chunyu
chunyuzeng01@163.com+86 13983624369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026